Thank you for your interest in the AHEAD Study. We have completed recruiting new participants. For more information about Alzheimer’s disease research opportunities, please visit the Learn More page. 


Time is running out to participate.

Brain changes related to Alzheimer’s disease can begin up to 20 years before a person notices any symptoms. The AHEAD Study is testing an investigational treatment aimed at delaying memory loss before noticeable signs of Alzheimer’s disease begin.

We are looking for people ages 55-80 who do not have noticeable symptoms of Alzheimer’s disease, but who are interested in participating in clinical trials aiming to help prevent potential future memory problems. Answer a few short questions to learn if you may be eligible to participate in the AHEAD Study, funded by the National Institutes of Health (NIH) and Eisai, Inc.

Participants eligible for the AHEAD Study:


Are healthy adults ages 55-80


Have not been diagnosed with Alzheimer’s or another dementia


Have a study partner, either a relative or close friend, who will participate in one study visit per year


Are willing to undergo blood and imaging tests to assess for levels of a protein in the brain called amyloid and learn the results

About Lecanemab:
The Investigational Treatment Being Tested in the

On July 6, 2023, lecanemab was granted full approval by the Food and Drug Administration (FDA) to treat people who already have cognitive impairment and mild dementia due to Alzheimer’s disease. Lecanemab has previously received accelerated approval for its demonstration of reducing amyloid plaque accumulation in the brain.

The AHEAD Study builds on the positive results that lecanemab showed in people with mild cognitive impairment or mild dementia. This study is testing the effects of lecanemab in people who have no cognitive symptoms of Alzheimer’s disease, but in whom tests indicate amyloid is present in the brain by assessing whether initiating lecanemab in people with amyloid plaques before symptoms start may help prevent cognitive decline. 

For participants enrolled in the AHEAD Study:

Participants can receive lecanemab even if they were assigned to placebo, if:

  • They complete the study’s full duration, or

  • They experience progression to mild cognitive impairment or dementia during the study and are deemed appropriate for treatment based on the FDA approval of lecanemab

The AHEAD Study has more than 70 locations across the United States and Canada.

Enter your ZIP code to find your nearest location or call 1-800-AHEAD-70.

Participant transportation may be provided for study visits.

Now Enrolling Coming Soon/On Hold